Although promising, the level of evidence is low, consisting of small, highly selective, and retrospective series with potential confounding biases related to glioblastoma biology (IDH1/2 mutations status, MGMT promoter methylation status) [3,20,24,41,42]. This evidence concerns the gene MGMT and glioblastoma.